Cipla Ltd
CIPLACipla Ltd
CIPLA
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 30.78 | 4.04 | 0.72% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 40.65 | 4.77 | 0.76% |
Forecast & Ratings
Detailed Forecastfrom 35 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Cipla Limited is a pharmaceutical company. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology & cosmetology, diabetes, HIV/AIDS, infectious diseases & critical care, malaria etc.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 11,510.99 | 13,998.31 | 14,622.98 | 15,513.36 | 16,838.98 | 17,476.19 | 19,425.58 | 22,044.25 | 23,228.57 | 24,215.13 | ||||||||||
Raw Materials | 4,533.92 | 5,026.31 | 5,206.16 | 5,671.36 | 5,737.45 | 6,236.18 | 7,544.60 | 9,220.29 | 8,348.28 | 18,511.71 | ||||||||||
| Power & Fuel Cost | 228.28 | 245.92 | 251.73 | 298.82 | 335.11 | 327.43 | 308.26 | 331.03 | 353.61 | |||||||||||
| Employee Cost | 1,967.72 | 2,434.01 | 2,633.82 | 2,690.10 | 2,856.53 | 3,027.01 | 3,251.83 | 3,529.91 | 3,830.08 | |||||||||||
| Selling & Administrative Expenses | 1,607.10 | 1,904.00 | 2,157.79 | 2,353.98 | 2,734.65 | 2,895.69 | 2,417.36 | 3,141.75 | 3,502.92 | |||||||||||
| Operating & Other expenses | 846.72 | 1,700.19 | 1,669.00 | 1,392.59 | 1,601.36 | 1,439.69 | 1,385.11 | 1,169.70 | 1,873.68 | |||||||||||
EBITDA | 2,327.25 | 2,687.88 | 2,704.48 | 3,106.51 | 3,573.88 | 3,550.19 | 4,518.42 | 4,651.57 | 5,320.00 | 5,703.42 | ||||||||||
| Depreciation/Amortization | 504.71 | 754.22 | 1,322.93 | 1,322.82 | 1,326.31 | 1,174.65 | 1,067.66 | 1,051.95 | 1,172.11 | 1,156.91 | ||||||||||
| PBIT | 1,822.54 | 1,933.66 | 1,381.55 | 1,783.69 | 2,247.57 | 2,375.54 | 3,450.76 | 3,599.62 | 4,147.89 | 4,546.51 | ||||||||||
| Interest & Other Items | 168.29 | 206.63 | 159.38 | 114.23 | 168.43 | 197.36 | 160.70 | 106.35 | 109.54 | 108.12 | ||||||||||
| PBT | 1,654.25 | 1,727.03 | 1,222.17 | 1,669.46 | 2,079.14 | 2,178.18 | 3,290.06 | 3,493.27 | 4,038.35 | 4,438.39 | ||||||||||
| Taxes & Other Items | 473.48 | 367.04 | 215.78 | 258.93 | 551.44 | 631.66 | 885.19 | 976.52 | 1,236.44 | 1,327.18 | ||||||||||
| Net Income | 1,180.77 | 1,359.99 | 1,006.39 | 1,410.53 | 1,527.70 | 1,546.52 | 2,404.87 | 2,516.75 | 2,801.91 | 3,111.21 | ||||||||||
| EPS | 14.71 | 16.93 | 12.52 | 17.53 | 18.97 | 19.19 | 29.82 | 31.20 | 34.72 | 38.55 | ||||||||||
| DPS | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 4.00 | 5.00 | 5.00 | 8.50 | 5.00 | ||||||||||
| Payout ratio | 0.14 | 0.12 | 0.16 | 0.17 | 0.16 | 0.21 | 0.17 | 0.16 | 0.24 | 0.13 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Cipla Ltd | 34.18 | 4.04 | 0.72% |
| Sun Pharmaceutical Industries Ltd | 32.81 | 4.69 | 0.99% |
| Dr Reddy's Laboratories Ltd | 20.63 | 3.99 | 0.72% |
| Mankind Pharma Ltd | 56.10 | 9.43 | — |
Price Comparison
Compare CIPLA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Decreased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has decreased by 1.97%
Shareholding Pattern
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Cipla Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
HDFC Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 2.0609% | Percentage of the fund’s portfolio invested in the stock 5.01% | Change in the portfolio weight of the stock over the last 3 months 1.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 5/51 (+7) |
SBI Equity Hybrid Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.4720% | Percentage of the fund’s portfolio invested in the stock 2.31% | Change in the portfolio weight of the stock over the last 3 months 0.40% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/103 (+3) |
HDFC TAX SAVER - DIRECT PLAN - GROWTH OPTION Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6022% | Percentage of the fund’s portfolio invested in the stock 5.01% | Change in the portfolio weight of the stock over the last 3 months 1.39% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 6/40 (+5) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Cipla Ltd
Events
Dividend Trend
No Dividend Cuts
CIPLA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.73%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.30 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 21, 2023
Dividend/Share
₹8.50
Ex DateEx Date
Jul 21, 2023
Cash Dividend
Ex DateEx DateAug 8, 2022
Dividend/Share
₹5.00
Ex DateEx Date
Aug 8, 2022
Cash Dividend
Ex DateEx DateAug 9, 2021
Dividend/Share
₹5.00
Ex DateEx Date
Aug 9, 2021
Cash Dividend
Ex DateEx DateMar 19, 2020
Dividend/Share
₹1.00
Ex DateEx Date
Mar 19, 2020
Cash Dividend
Ex DateEx DateMar 19, 2020
Dividend/Share
₹3.00
Ex DateEx Date
Mar 19, 2020
News & Opinions
Stock Market Live: GIFT Nifty Signals Lower Open; Maruti, Cipla, Vedanta, RVNL, RBL Bank In Focus
33 minutes ago•Bloomberg Quint
Stocks To Watch: HDFC Bank, Maruti Suzuki, Cipla, Vedanta, Hero MotoCorp, RVNL, Kalpataru Projects, RBL Bank
2 hours ago•Bloomberg Quint
Pharma Sector Check - Can Indian Generic Players Mitigate The Revlimid Cliff? Systematix
4 days ago•Bloomberg Quint
Stocks to Watch: Delta Corp, Infosys, Cipla, Vedanta, PNB, Sai Silks, and Others - News18
5 days ago•News18
Stocks to Watch: Infosys, SJVN, SBI, Cipla, Apollo Tyres, DBC Bank, Zydus, and Others - News18
1 week ago•News18
Stocks To Watch: Infosys, SBI, Cipla, InterGlobe Aviation, SJVN, Biocon, Apollo Tyres, Exide Industries, REC
1 week ago•Bloomberg Quint
Stocks to Watch: HDFC Bank, RR Kabel, Tata Motors, Cipla, Coal India, Biocon, and Others - News18
1 week ago•News18
Healthcare I U.S. Generics - Turning The Tide? Motilal Oswal’s Thematic View
2 weeks ago•Bloomberg Quint
Stocks to Watch: Tata Motors, Cipla, Infosys, Zee Ent, Vedanta, Sun Pharma, and Others - News18
2 weeks ago•News18
Cipla Founding Family’s Stake Sale In Jeopardy Over $13 Billion Valuation Target
2 weeks ago•Bloomberg Quint
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 8.41%, vs industry avg of 8.45%
Decreasing Market Share
Over the last 5 years, market share decreased from 7.64% to 7.31%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 14.71%, vs industry avg of 9.81%